Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Geron Corp. -- Ignore unavailable to you. Want to Upgrade?

To: manohar kanuri who wrote (2225)	1/19/2000 12:45:00 PM
From: ahhaha	Read Replies (2) \| Respond to of 3576

It isn't huge, maybe only only large, but it is reassuring. The shares are being run by smaller players who don't know what they're doing. Not much institutional activity because the institutions move according to their assessments of secret conversations with analysts. The analysts don't quite understand why the stock is running. The reason is that there is a growing perception among the scientific community that telomerase regulation technology in contradistinction to specific pathogenic application can be applied with leverage in unexpected areas outside of the company's apparent focus. The patent helps to firm conviction that these undiscovered applications' returns will stay within the company. The company hopes to integrate telomerase tech with the patent's nuclear transfer so that the body doesn't reject cells gaining "immortality". The little players are inadvertently discovering this growing perception.